Mary Mosher

Array ( [id] => 9838522 [patent_doc_number] => 20150030602 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-29 [patent_title] => 'ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF AFFECTIVE AND ANXIETY DISORDERS' [patent_app_type] => utility [patent_app_number] => 14/364590 [patent_app_country] => US [patent_app_date] => 2013-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 18800 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14364590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785700 [patent_doc_number] => 20140302520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'METABOLISM OF SOD1 IN CSF' [patent_app_type] => utility [patent_app_number] => 14/352560 [patent_app_country] => US [patent_app_date] => 2012-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 5939 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14352560 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8883567 [patent_doc_number] => 20130156751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-20 [patent_title] => 'TREATMENT OF DISEASES' [patent_app_type] => utility [patent_app_number] => 13/544026 [patent_app_country] => US [patent_app_date] => 2012-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 4555 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13544026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9396980 [patent_doc_number] => 20140094386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-03 [patent_title] => 'METHODS OF DETERMINING A TREATMENT PROTOCOL FOR AND/OR A PROGNOSIS OF A PATIENT\'S RECOVERY FROM A BRAIN INJURY RESULTING FROM A HYPOXIC EVENT' [patent_app_type] => utility [patent_app_number] => 14/111331 [patent_app_country] => US [patent_app_date] => 2012-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 23933 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14111331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8713375 [patent_doc_number] => 08399514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-03-19 [patent_title] => 'Treatment for multiple sclerosis' [patent_app_type] => utility [patent_app_number] => 13/372426 [patent_app_country] => US [patent_app_date] => 2012-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10880 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13372426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8317474 [patent_doc_number] => 08232250 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-07-31 [patent_title] => 'Low frequency glatiramer acetate therapy' [patent_app_type] => utility [patent_app_number] => 13/308299 [patent_app_country] => US [patent_app_date] => 2011-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8130 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13308299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7719874 [patent_doc_number] => 20120009209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-12 [patent_title] => 'ENRICHMENT AND PURIFICATION OF INFECTIOUS PRION PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/157216 [patent_app_country] => US [patent_app_date] => 2011-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 7631 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0009/20120009209.pdf [firstpage_image] =>[orig_patent_app_number] => 13157216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7696701 [patent_doc_number] => 20110229889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-22 [patent_title] => 'DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Msx1/2' [patent_app_type] => utility [patent_app_number] => 13/071450 [patent_app_country] => US [patent_app_date] => 2011-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 16487 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0229/20110229889.pdf [firstpage_image] =>[orig_patent_app_number] => 13071450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6125419 [patent_doc_number] => 20110086034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-14 [patent_title] => 'NUCLEOTIDE AND PROTEIN SEQUENCES OF NOGO GENES AND METHODS BASED THEREON' [patent_app_type] => utility [patent_app_number] => 12/903300 [patent_app_country] => US [patent_app_date] => 2010-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 41 [patent_no_of_words] => 11433 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0086/20110086034.pdf [firstpage_image] =>[orig_patent_app_number] => 12903300 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8713273 [patent_doc_number] => 08399413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-03-19 [patent_title] => 'Low frequency glatiramer acetate therapy' [patent_app_type] => utility [patent_app_number] => 12/806684 [patent_app_country] => US [patent_app_date] => 2010-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8112 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12806684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6280008 [patent_doc_number] => 20100119450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-13 [patent_title] => 'SOLUBLE LOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN BINDS DIRECTLY TO ALZHEIMER\'S AMYLOID-BETA PEPTIDE' [patent_app_type] => utility [patent_app_number] => 12/607049 [patent_app_country] => US [patent_app_date] => 2009-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13787 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0119/20100119450.pdf [firstpage_image] =>[orig_patent_app_number] => 12607049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6528706 [patent_doc_number] => 20100015145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-01-21 [patent_title] => 'Use of a compound for reducing the biological effectiveness of IL-6' [patent_app_type] => utility [patent_app_number] => 12/585545 [patent_app_country] => US [patent_app_date] => 2009-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4049 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0015/20100015145.pdf [firstpage_image] =>[orig_patent_app_number] => 12585545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6475534 [patent_doc_number] => 20100284962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-11-11 [patent_title] => 'MODIFIED TUMOR NECROSIS FACTOR-BETA' [patent_app_type] => utility [patent_app_number] => 12/436440 [patent_app_country] => US [patent_app_date] => 2009-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10068 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0284/20100284962.pdf [firstpage_image] =>[orig_patent_app_number] => 12436440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5354689 [patent_doc_number] => 20090186033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-07-23 [patent_title] => 'ANTI-AMYLOID IMMUNOGENIC COMPOSITIONS, METHODS AND USES' [patent_app_type] => utility [patent_app_number] => 12/364996 [patent_app_country] => US [patent_app_date] => 2009-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5805 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0186/20090186033.pdf [firstpage_image] =>[orig_patent_app_number] => 12364996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6616353 [patent_doc_number] => 20100003243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-01-07 [patent_title] => 'Uses and Compositions for treatment of Psoriasis and Crohn\'s Disease' [patent_app_type] => utility [patent_app_number] => 12/352503 [patent_app_country] => US [patent_app_date] => 2009-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62633 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0003/20100003243.pdf [firstpage_image] =>[orig_patent_app_number] => 12352503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6275121 [patent_doc_number] => 20100256043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-07 [patent_title] => 'USE OF A PEPTIDE AS A THERAPEUTIC AGENT' [patent_app_type] => utility [patent_app_number] => 12/677753 [patent_app_country] => US [patent_app_date] => 2008-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33961 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0256/20100256043.pdf [firstpage_image] =>[orig_patent_app_number] => 12677753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6506618 [patent_doc_number] => 20100210540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-08-19 [patent_title] => 'USE OF THE PEPTIDE COMBINATION THYMOSIN BETA 4 AND DELTA SLEEP INDUCING PEPTIDE AS A THERAPEUTIC AGENT' [patent_app_type] => utility [patent_app_number] => 12/677804 [patent_app_country] => US [patent_app_date] => 2008-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36481 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0210/20100210540.pdf [firstpage_image] =>[orig_patent_app_number] => 12677804 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5264880 [patent_doc_number] => 20090117565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2009-05-07 [patent_title] => 'Compositions and methods for diagnosis and treating mood disorders' [patent_app_type] => utility [patent_app_number] => 12/154419 [patent_app_country] => US [patent_app_date] => 2008-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 32178 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0117/20090117565.pdf [firstpage_image] =>[orig_patent_app_number] => 12154419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6576670 [patent_doc_number] => 20100047243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-02-25 [patent_title] => 'NOVEL ANTIBODIES AGAINST IGF-IR' [patent_app_type] => utility [patent_app_number] => 12/526966 [patent_app_country] => US [patent_app_date] => 2008-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 34800 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0047/20100047243.pdf [firstpage_image] =>[orig_patent_app_number] => 12526966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6252054 [patent_doc_number] => 20100028356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-02-04 [patent_title] => 'METHOD OF DIAGNOSING A NEURODEGENERATIVE DISEASE' [patent_app_type] => utility [patent_app_number] => 12/526481 [patent_app_country] => US [patent_app_date] => 2008-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 28933 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0028/20100028356.pdf [firstpage_image] =>[orig_patent_app_number] => 12526481 [rel_patent_id] =>[rel_patent_doc_number] =>)